TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11521332
Drug: Acetylsalicylic acid,
Normalized name: Acetylsalicylic Acid, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic acid, lipid-lowering drugs, vitamins, and exercise (primary preventive effects)
Study: 31751758
Drug: Antihistamine therapy
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine therapy
Study: 31751758
Drug: Cyclospirine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclospirine therapy
Study: 28941141
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of ortho-silicic acid stabilized by hydrolyzed collagen (group 1)
Study: 22944873
Drug: Early integrated
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early integrated treatment group (ART within 4 weeks of tuberculosis treatment initiation)
Study: 22944873
Drug: Late integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late integrated treatment group (ART within 4 weeks of completion of the intensive phase of tuberculosis treatment)
Study: 22944873
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment group (ART within 4 weeks after tuberculosis therapy completion)
Study: 20090313
Drug: Pullulan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pullulan (12 g/day)
Study: 20090313
Drug: Promitor Resistant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Promitor Resistant Starch (12 g/day)
Study: 20090313
Drug: Soluble fiber
Normalized name: Soluble fiber
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble fiber dextrin (12 g/day)
Study: 20090313
Drug: Promitor Soluble
Normalized name: Domitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promitor Soluble Corn Fiber (12 g/day)
Study: 20090313
Drug: All fibers
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All fibers (12 g/day)
Study: 17255841
Drug: Low osmolarity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low osmolarity WHO-ORS (G-ORS) and rice-based ORS (R-ORS) combined as control
Study: 15377472
Drug: CHOP +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP + G-CSF
Study: 9590570
Drug: Captopril (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25-100 mg daily)
Study: 9590570
Drug: Atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50-100 mg daily)
Study: 3281774
Drug: Codeine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (120 mg)
Study: 31339789
Drug: Quadrivalent influenza
Normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent influenza vaccine (QIV) information and education
Study: 31339789
Drug: Concern that
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concern that vaccines need to be carefully administered
Study: 31339789
Drug: Mistrust of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistrust of new vaccines
Study: 30213012
Drug: High-dose IFNα‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFNα‐2b (9 million IU)
Study: 30213012
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-dose IFNα‐2b and red light therapy
Study: 30213012
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant IFNα‐2b (1 million IU)
Study: 24656288
Drug: Sitaxentan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxentan 50 mg
Study: 14967189
Drug: Nicotine-patch therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine-patch therapy for 8 weeks
Study: 14967189
Drug: Nicotine-patch therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine-patch therapy
Study: 9272748
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide treatment
Study: 3066967
Drug: Ryodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ryodipine (30 mg single dose)
Study: 3066967
Drug: Ryodipine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ryodipine (150 mg/day for a short period)
Study: 3066967
Drug: Ryodipine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ryodipine (150 mg/day)
Study: 3066967
Drug: Ryodipine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ryodipine (250 mg/day)
Study: 31209710
Drug: Ultrasound-guided local
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided local insulin injection
Study: 31209710
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 40 mg methylprednisolone acetate
Study: 31209710
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection followed by insulin injection twice after 2 and 4 weeks
Study: 12929098
Drug: Rotational atherectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotational atherectomy (RA) and adjunctive balloon angioplasty (PTCA)
Study: 8471818
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day n‐3 fatty acids
Study: 8471818
Drug: 4.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g/day n‐3 fatty acids
Study: 8471818
Drug: n‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 fatty acids treatment
Study: 3899152
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) 0.5 mg i.v.
Study: 17080448
Drug: Integrative cognitive-affective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative cognitive-affective therapy
Study: 17080448
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment approaches
Study: 17080448
Drug: Treatment modeling
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment modeling
Study: 15631318
Drug: omeprazole and
Normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: omeprazole and amoxicillin (OA)
Study: 15631318
Drug: omeprazole, amoxicillin
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole, amoxicillin and tinidazole (OAT)
Study: 11414346
Drug: Random treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random treatment assignment
Study: 9715740
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (10 g day-1)
Study: 7839282
Drug: Intramuscular magnesium
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular magnesium sulphate regimen (loading dose of 14 g: 4 g i.v. and 10 g IM, followed by 5 g 4-hourly)
Study: 7839282
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate regimen (loading dose of 6 g i.v., followed by maintenance infusion of 2 g/h)
Study: 3402353
Drug: Urapidil 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 25 mg intravenously
Study: 30561313
Drug: Cotrimoxazole preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole preventive therapy
Study: 30561313
Drug: Antibacterial drugs
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial drugs (general)
Study: 28097295
Drug: Systemic β-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic β-blocker use
Study: 25730540
Drug: Water-soluble polyantimicrobial
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-soluble polyantimicrobial gel (BWG)
Study: 20656508
Drug: Actual weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual weight-based dose of IV t-PA (administered dose divided by actual weight, capped at 100 kg)
Study: 20656508
Drug: Actual weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual weight-based dose of IV t-PA
Study: 17299064
Drug: Pio (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pio (7.5 mg/d) + Flu (62.5 mg/d) + Met (850 mg/d) + transdermal estroprogestagen
Study: 17299064
Drug: Flu (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu (62.5 mg/d) + Met (850 mg/d) + transdermal estroprogestagen
Study: 15159232
Drug: WB (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: WB (12 g fiber/d)
Study: 15159232
Drug: WBRS (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRS (12 g WB fiber/d plus 22 g RS/d)
Study: 12743147
Drug: Supportive-expressive (SE)
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive (SE) therapy group
Study: 12743147
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (SE therapy and control)
Study: 10426704
Drug: High-vegetable diet
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-vegetable diet (490 g/d)
Study: 10426704
Drug: Low-vegetable diet
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-vegetable diet supplemented with beta-carotene (6 mg/d) and lutein (9 mg/d)
Study: 10426704
Drug: Low-vegetable diet
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-vegetable diet (130 g/d)
Study: 7750429
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate (120 mmol daily for 8 weeks)
Study: 7750429
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride (120 mmol daily for 8 weeks)
Study: 2180461
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (n = 41)
Study: 2180461
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg nocte (n = 38)
Study: 24471979
Drug: MAL-PDT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL-PDT treatment
Study: 22902599
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg 8-hourly starting the afternoon before surgery until the fifth postoperative day
Study: 16297748
Drug: Combined sciatic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatic and femoral nerve blocks with 40 mL of 0.375% bupivacaine
Study: 12239138
Drug: Epoetin (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin (subcutaneous, 150 U/kg thrice weekly for a minimum of 4 weeks)
Study: 12239138
Drug: Epoetin (weekly,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin (weekly, 40,000 U/wk)
Study: 12239138
Drug: Epoetin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin (dose escalation if no response)
Study: 12239138
Drug: Epoetin (titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin (titration once Hgb reaches 12 g/dL)
Study: 12239138
Drug: Epoetin for
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin for patients with anemia associated with low-risk myelodysplasia not receiving chemotherapy
Study: 12239138
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for anemic patients with hematologic malignancies
Study: 30908627
Drug: Attachment-based family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-based family therapy therapist interventions (relational reframes and focus on primary adaptive emotions)
Study: 30908627
Drug: Attachment-based family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-based family therapy therapist interventions (interpretations, reassurances, and focus on rejecting anger toward parents)
Study: 30908627
Drug: Attachment-based family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-based family therapy therapist interventions (general encouragement of affect and focus on unmet attachment/identity needs)
Study: 27586686
Drug: Weekly diary
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly diary
Study: 24095239
Drug: Injection technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection technique with traction
Study: 24095239
Drug: Injection technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection technique without traction
Study: 9491842
Drug: High vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High vancomycin trough serum levels (> 15 microg/mL)
Study: 9491842
Drug: Low vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low vancomycin trough serum levels (< 15 microg/mL)
Study: 30317420
Drug: 5% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sodium hypochlorite as a haemostatic agent
Study: 24054874
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus (1.0×10(8) CFU, twice daily)
Study: 24054874
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (twice daily)
Study: 16609107
Drug: Laser-assisted anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-assisted anesthesia (Er:YAG unit, fluence 3.5 J/cm2, pulse width 600 microseconds, spot diameter 6 mm) with lidocaine 4% cream
Study: 16609107
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser with lidocaine 4% cream
Study: 10826853
Drug: tPA (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA (0.25 mg/kg/day in 0.9% saline) for 3 days
Study: 1321186
Drug: Candoxatril 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 200 mg twice daily
Study: 29969907
Drug: Citalopram for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram for the treatment of agitation
Study: 25675290
Drug: Oral cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cefuroxime axetil 500 mg dose, twice daily for 3 days
Study: 25675290
Drug: Parenteral cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral cefuroxime axetil 750 mg IV dose, single dose before placement
Study: 24680330
Drug: Systemic application
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic application of dexamethasone (DEX) 10 mg×3 d followed by 5 mg×4 d
Study: 24680330
Drug: Topical injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL TOPICAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical injection of methylprednisolone sodium succinate 40 mg every three days
Study: 24680330
Drug: Local corticosteroids
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroids injection in low‐middle frequencies
Study: 18165444
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine 0.5 g/kg/d during the first 24 hours of resuscitation and 10 days thereafter
Study: 15242433
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 20 micrograms/kg
Study: 7962302
Drug: L-692,429 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-692,429 (0.2 mg/kg)
Study: 7962302
Drug: L-692,429 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-692,429 (0.75 mg/kg)
Study: 2853764
Drug: metoprolol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol + terbutaline (10 mg/day + 200 mg/day)
Study: 2853764
Drug: metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (200 mg/day)
Study: 2853764
Drug: terbutaline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline (10 mg/day)
Study: 2853764
Drug: orciprenaline (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: orciprenaline (30 mg/day)
Study: 26657184
Drug: CMV glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV glycoprotein B (gB) vaccine with MF59
Study: 20052549
Drug: Spinach preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinach preparation
Study: 20052549
Drug: Perilla preparation
Normalized name: PERILLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilla preparation
Study: 18780315
Drug: Cisplatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (20 mg/m²/day, Days 1-5) and Vinorelbine (6 mg/m² bolus on Day 1 and 6 mg/m²/day continuous infusion on Days 1-5) with concurrent 30-gray fractionated external-beam radiotherapy
Study: 18780315
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and Vinorelbine with concurrent radiotherapy
Study: 15911360
Drug: Adjunctive lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive lamotrigine therapy for 16 weeks
Study: 15911360
Drug: Lamotrigine monotherapy
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine monotherapy for 12 weeks
Study: 12769163
Drug: Indapamide SR
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide SR 1.5 mg once a day
Study: 12769163
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg once a day
Study: 12769163
Drug: Amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5-10 mg (1st step)
Study: 12769163
Drug: Atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50-100 mg (2nd step)
Study: 10654588
Drug: Phytosterol ester-enriched
Normalized name: phytosterol esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol ester-enriched margarine (8.6 g vegetable oil phytosterols)
Study: 1650023
Drug: Rapid Infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Infusion System (RIS)
Study: 1650023
Drug: Conventional Fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Fluid Administration (CFA)
Study: 6849742
Drug: Practolol 50
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol 50 mg
Study: 30621276
Drug: L-Valine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Valine 0.15 kcal/min (total: 3.3 g)
Study: 30621276
Drug: L-Valine 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Valine 0.45 kcal/min (total: 9.9 g)
Study: 28881472
Drug: Domagrozumab 10
Normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab 10 mg/kg IV (single dose)
Study: 28881472
Drug: Domagrozumab 10
Normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab 10 mg/kg IV (multiple doses)
Study: 28881472
Drug: Domagrozumab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab (various doses IV and SC)
Study: 28881472
Drug: Domagrozumab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab (various doses)
Study: 28881472
Drug: Domagrozumab 20
Normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab 20 mg/kg IV
Study: 26847437
Drug: Sputum-based markers
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sputum-based markers of speed of clearance of bacilli (time to smear negative status, time to culture negative status on LJ or in MGIT, daily rate of change of log10(TTP) to day 56)
Study: 25888092
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pethidine i.v.
Study: 23094932
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment for the same time period
Study: 12453973
Drug: Inhaled regular
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled regular insulin (INH) via Aerodose Insulin Inhaler, 240 units
Study: 12453973
Drug: Inhaled regular
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled regular insulin (INH)
Study: 12453973
Drug: Subcutaneously injected
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injected regular insulin (SC)
Study: 30646314
Drug: Levocarnitine (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocarnitine (18 g)
Study: 30646314
Drug: Levocarnitine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocarnitine (12 g)
Study: 30646314
Drug: Levocarnitine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocarnitine (6 g)
Study: 24498404
Drug: School-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based physical activity program (KISS) including daily physical education (two additional lessons per week), short physical activity breaks, and daily physical activity homework.
Study: 21945258
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg of hemagglutinin antigen without adjuvant
Study: 21945258
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg of hemagglutinin antigen with aluminum hydroxide, MPL and squalene
Study: 21945258
Drug: 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 μg of hemagglutinin antigen with aluminum hydroxide and MPL
Study: 21945258
Drug: 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 μg of hemagglutinin antigen with aluminum hydroxide and squalene
Study: 11896424
Drug: Cyclophosphamide (CPM)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CPM) 5 g/m(2)